Primary care providers want to have these conversations but sometimes worry about coming across as judgmental
Comparing Cost, Access, and Treatment Flexibility Brand-name Ozempic and Zepbound carry significant out-of-pocket costs for uninsured patients, with monthly prescriptions ranging $900-$1,500 depending on dose
Preclinical studies have demonstrated that liraglutide significantly suppresses obesity-associated breast cancer cell proliferation via modulation of adipokine expression, with enhanced antineoplastic effects observed in obese populations [122]
theoretical concern for melanoma risk with chronic use Appetite suppression : Significant in some users
It is essential to note that tirzepatide has no FDA-approved indication for treating substance use disorders
106(4): 128590 Pressley JC, Louis ED, Tang MX, et al